Earnings Beat: Global Health Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Global Health Limited (NSE:MEDANTA) defied analyst predictions to release its second-quarter results, which were ahead of market expectations. It was overall a positive result, with revenues beating expectations by 9.6% to hit ₹15b. Global Health reported statutory earnings per share (EPS) ₹8.20, which was a notable 18% above what the analysts had forecast. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Global Health after the latest results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from Global Health's 19 analysts is for revenues of ₹53.1b in 2027. This would reflect a credible 5.1% increase on its revenue over the past 12 months. Per-share earnings are expected to swell 15% to ₹26.51. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹53.1b and earnings per share (EPS) of ₹26.51 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for Global Health

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹1,593. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Global Health, with the most bullish analyst valuing it at ₹1,799 and the most bearish at ₹1,390 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Global Health is an easy business to forecast or the the analysts are all using similar assumptions.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Global Health's past performance and to peers in the same industry. We would highlight that Global Health's revenue growth is expected to slow, with the forecast 11% annualised growth rate until the end of 2027 being well below the historical 16% p.a. growth over the last three years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 18% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Global Health.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at ₹1,593, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Global Health going out to 2029, and you can see them free on our platform here.

We also provide an overview of the Global Health Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.